The Midlife in the United States Study - Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to solicit an Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD)-focused U01 that is ancillary to, but integrated with, the Midlife in the United States Study (MIDUS) U19 (see PAR-21-156) to provide in-depth information to elucidate behavioral, social, psychological and biological pathways of risk and resilience to cognitive decline and AD/ADRD. In addition to capitalizing on already-collected data, new measures should be included to test hypotheses regarding development of AD/ADRD via cumulative stress exposures over 30 prior years of data collection. As well, the research should examine the protective influence of psychosocial resources, affective style, and lifestyle factors assessed over multiple prior waves of MIDUS. The new assessments on two national samples with many years of information on potential influences on AD/ADRD hold potential for yielding invaluable insights relevant for preventative interventions and treatments in future studies.


  • Letter of Intent Due Date(s): New Dates March 26, 2021; July 16, 2021; and January 1, 2022

  • Application Due Date(s): April 26, 2021; Aug 16, 2021; Feb 1, 2022

PAR-21-157 Expiration Date New Date February 2, 2022 per issuance of NOT-AG-21-025. (Original Expiration Date: November 19, 2021)




Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational
Social Sciences

External Deadline

February 1, 2022